|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Valsecchi ME, Díaz-Cantón E, de la Vega M
and Littman SJ: Recent treatment advances and novel therapies in
pancreas cancer: A review. J Gastrointest Cancer. 45:190–201.
2014.PubMed/NCBI
|
|
3
|
Vaccaro V, Gelibter A, Bria E, Iapicca P,
Cappello P, Di Modugno F, Pino MS, Nuzzo C, Cognetti F, Novelli F,
et al: Molecular and genetic bases of pancreatic cancer. Curr Drug
Targets. 13:731–743. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
National Cancer Institute of Canada Clinical Trials Group:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Won E, Janjigian YJ and Ilson DH: HER2
directed therapy for gastric/esophageal cancers. Curr Treat Options
Oncol. 15:395–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rimawi MF, Schiff R and Osborne CK:
Targeting HER2 for the treatment of breast cancer. Annu Rev Med.
66:111–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Larbouret C, Robert B, Navarro-Teulon I,
Thèzenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP,
Pèlegrin A and Azria D: In vivo therapeutic synergism of
anti-epidermal growth factor receptor and anti-HER2 monoclonal
antibodies against pancreatic carcinomas. Clin Cancer Res.
13:3356–3362. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xia W, Mullin RJ, Keith BR, Liu LH, Ma H,
Rusnak DW, Owens G, Alligood KJ and Spector NL: Anti-tumor activity
of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation
of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene.
21:6255–6263. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cameron D, Casey M, Press M, Lindquist D,
Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B,
Crown J, et al: A phase III randomized comparison of lapatinib plus
capecitabine versus capecitabine alone in women with advanced
breast cancer that has progressed on trastuzumab: Updated efficacy
and biomarker analyses. Breast Cancer Res Treat. 112:533–543. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Walther A, Johnstone E, Swanton C, Midgley
R, Tomlinson I and Kerr D: Genetic prognostic and predictive
markers in colorectal cancer. Nat Rev Cancer. 9:489–499. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Drakaki A and Iliopoulos D: MicroRNA-gene
signaling pathways in pancreatic cancer. Biomed J. 36:200–208.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garofalo M, Romano G, Di Leva G, Nuovo G,
Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al:
EGFR and MET receptor tyrosine kinase-altered microRNA expression
induces tumorigenesis and gefitinib resistance in lung cancers. Nat
Med. 18:74–82. 2012.
|
|
16
|
Seike M, Goto A, Okano T, Bowman ED,
Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, et
al: MiR-21 is an EGFR-regulated anti-apoptotic factor in lung
cancer in never-smokers. Proc Natl Acad Sci USA. 106:12085–12090.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chou YT, Lin HH, Lien YC, Wang YH, Hong
CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, et al: EGFR promotes
lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc
pathway that targets the Ets2 transcriptional repressor ERF. Cancer
Res. 70:8822–8831. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Larbouret C, Gaborit N, Chardès T, Coelho
M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B and
Pèlegrin A: In pancreatic carcinoma, dual EGFR/HER2 targeting with
cetuximab/trastuzumab is more effective than treatment with
trastuzumab/erlotinib or lapatinib alone: Implication of receptors'
down-regulation and dimers' disruption. Neoplasia. 14:121–130.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
LaConti JJ, Shivapurkar N, Preet A, Mays
Deslattes A, Peran I, Kim SE, Marshall JL, Riegel AT and Wellstein
A: Tissue and serum microRNAs in the Kras(G12D) transgenic animal
model and in patients with pancreatic cancer. PLoS One.
6:e206872011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shivapurkar N, Weiner LM, Marshall JL,
Madhavan S, Mays Deslattes A, Juhl H and Wellstein A: Recurrence of
early stage colon cancer predicted by expression pattern of
circulating microRNAs. PLoS One. 9:e846862014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Andersson R, Aho U, Nilsson BI, Peters GJ,
Pastor-Anglada M, Rasch W and Sandvold ML: Gemcitabine
chemoresistance in pancreatic cancer: Molecular mechanisms and
potential solutions. Scand J Gastroenterol. 44:782–786. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ghaneh P, Kawesha A, Evans JD and
Neoptolemos JP: Molecular prognostic markers in pancreatic cancer.
J Hepatobiliary Pancreat Surg. 9:1–11. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sarkar S, Dubaybo H, Ali S, Goncalves P,
Kollepara SL, Sethi S, Philip PA and Li Y: Down-regulation of
miR-221 inhibits proliferation of pancreatic cancer cells through
up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer
Res. 3:465–477. 2013.PubMed/NCBI
|
|
25
|
Shivapurkar N, Mikhail S, Navarro R, Bai
W, Marshall J, Hwang J, Pishvaian M, Wellstein A and He AR:
Decrease in blood miR-296 predicts chemotherapy resistance and poor
clinical outcome in patients receiving systemic chemotherapy for
metastatic colon cancer. Int J Colorectal Dis. 28:8872013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kawaguchi T, Komatsu S, Ichikawa D,
Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T,
Hirajima S, et al: Clinical impact of circulating miR-221 in plasma
of patients with pancreatic cancer. Br J Cancer. 108:361–369. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Su A, He S, Tian B, Hu W and Zhang Z:
MicroRNA-221 mediates the effects of PDGF-BB on migration,
proliferation, and the epithelial-mesenchymal transition in
pancreatic cancer cells. PLoS One. 8:e713092013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Basu A, Alder H, Khiyami A, Leahy P, Croce
CM and Haldar S: MicroRNA-375 and MicroRNA-221: Potential noncoding
RNAs associated with antiproliferative activity of benzyl
isothiocyanate in pancreatic cancer. Genes Cancer. 2:108–119. 2011.
View Article : Google Scholar : PubMed/NCBI
|
